Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) saw some unusual options trading on Monday. Investors acquired 49,767 call options on the company. This represents an increase of 424% compared to the typical volume of 9,504 call options.
Wall Street Analyst Weigh In
SMMT has been the topic of several research reports. Morgan Stanley downgraded shares of Summit Therapeutics to an “outperform” rating in a research report on Tuesday, September 29th. HC Wainwright reaffirmed a “buy” rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. Stifel Nicolaus reduced their target price on shares of Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday, July 24th. Citigroup reissued a “market outperform” rating on shares of Summit Therapeutics in a research note on Tuesday, October 27th. Finally, Leerink Partners raised shares of Summit Therapeutics from an “underperform” rating to a “market perform” rating and raised their price target for the company from $12.00 to $13.00 in a report on Wednesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Summit Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.45.
View Our Latest Stock Report on SMMT
Hedge Funds Weigh In On Summit Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp lifted its position in Summit Therapeutics by 24.4% during the 1st quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock worth $71,000 after buying an additional 732 shares in the last quarter. Tidal Investments LLC grew its holdings in shares of Summit Therapeutics by 0.7% in the 2nd quarter. Tidal Investments LLC now owns 121,097 shares of the company’s stock valued at $1,764,000 after acquiring an additional 783 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Summit Therapeutics by 2.4% in the third quarter. Russell Investments Group Ltd. now owns 42,714 shares of the company’s stock valued at $722,000 after acquiring an additional 1,021 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Summit Therapeutics by 1.1% in the third quarter. State Board of Administration of Florida Retirement System now owns 95,254 shares of the company’s stock valued at $1,611,000 after acquiring an additional 1,025 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in Summit Therapeutics by 61.7% during the third quarter. GAMMA Investing LLC now owns 2,697 shares of the company’s stock worth $46,000 after acquiring an additional 1,029 shares in the last quarter. Institutional investors own 4.61% of the company’s stock.
Summit Therapeutics Trading Down 14.5%
Shares of NASDAQ:SMMT traded down $2.06 during trading on Monday, hitting $12.09. 14,150,151 shares of the company’s stock were exchanged, compared to its average volume of 4,689,564. The firm has a market cap of $9.67 billion, a P/E ratio of -11.25 and a beta of -1.49. The firm has a 50-day moving average price of $16.41 and a two-hundred day moving average price of $16.14. Summit Therapeutics has a 1-year low of $11.87 and a 1-year high of $29.23.
More Summit Therapeutics News
Investors following SMMT have been watching these news items:
- Neutral Sentiment: Barclays cut its price target to $18 from $20 and maintained an “equal weight” rating. The lower target reflects a more cautious outlook, although it remains above the price cited in the report. Barclays recommendations
- Negative Sentiment: The FDA issued a Complete Response Letter for Summit’s application seeking approval of ivonescimab with platinum-containing chemotherapy for certain patients with advanced or metastatic non-small cell lung cancer whose disease progressed after EGFR-targeted therapy. The application was not approved, delaying the drug’s potential commercialization; the company’s update did not specify the FDA’s concerns in the information provided. Summit Therapeutics’ ivonescimab application update
Summit Therapeutics Company Profile
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
See Also
- Five stocks we like better than Summit Therapeutics
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
